SK Biopharm "Aiming to Become a Top 10 Global Healthcare Company by 2030"

SK Biopharm CI (Photo by SK Biopharm)

[Asia Economy Reporter Lee Chun-hee] SK Biopharm announced its future vision, the 'Financial Story,' online on the 2nd.

SK Biopharm aims to become a 'Top 10 Global Healthcare Company by 2030' by pursuing four core strategies: accelerating its U.S. business through portfolio expansion, developing and executing differentiated growth models by region, expanding product development areas and continuously creating new pipelines, and innovating its research and development (R&D) platform using the latest technologies.

The company plans to strengthen its leadership in the neurological disorder field by continuously launching new products in the U.S. market, while simultaneously securing global competitiveness through new drug candidates and promising product acquisitions. In Europe and Asia, it will develop and implement various business models through strategic partnerships.

Innovative new drugs will expand the R&D scope from central nervous system diseases to brain diseases, focusing on four major disease groups: epilepsy, rare neurological diseases, psychiatric disorders, and cancer, continuously expanding the pipeline. Utilizing artificial intelligence (AI) and digital transformation (DT), the company will accelerate candidate substance discovery and create new drugs by integrating advanced ribonucleic acid (RNA) technology.

ESG management will also be intensified. SK Biopharm recently published its first sustainability report, establishing a roadmap with mid- to long-term action plans in five key focus areas: healthcare value creation, sustainable partnerships, capable and happy employees, transparent and ethical management, and minimizing environmental impact. In particular, aligned with the overall SK Group vision, it set the goal of achieving 'Net Zero carbon emissions by 2040.'

Jungwoo Cho, CEO of SK Biopharm, stated, “Based on the ‘Financial Story’ and ‘ESG management,’ we will faithfully fulfill our role as the central axis of SK Group’s pharmaceutical and bio business,” adding, “We will expand our portfolio beyond drug development into the healthcare sector and grow into a global top-tier company with a corporate value of 50 trillion won.”

This content was produced with the assistance of AI translation services.